LuciPem (Pemigatinib) 4.5mg*14 | Lucius Laos Generic | GLT

Generic Information: LuciPem (Pemigatinib) 4.5mg — Laos

LuciPem is a Lao-manufactured generic of pemigatinib from Lucius Pharmaceuticals (Lao) Co., Ltd., a Vientiane-based manufacturer with a broad portfolio of oncology generics for Southeast Asian and international patients. This listing is the 4.5 mg strength in a 14-tablet pack, matching the originator's lowest dose presentation. LuciPem offers a traceable, affordable alternative for FGFR2-altered cholangiocarcinoma, a rare and hard-to-treat bile duct cancer.

Lucius Pharmaceuticals uses a distinctive "Luci" prefix across its oncology line, so buyers familiar with other Lucius products will recognise LuciPem as its pemigatinib offering. The 4.5 mg strength is commonly used for dose titration or adjustment relative to the 13.5 mg once-daily standard, so patients should confirm their prescribed strength before ordering.

What Is LuciPem Used For?

LuciPem is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumour carries an FGFR2 fusion or rearrangement. This molecular alteration drives a subset of intrahepatic cholangiocarcinoma, a cancer that is often diagnosed at a late stage with limited options. Pemigatinib was the first targeted therapy developed specifically for this FGFR2-altered group.

How Does LuciPem Work?

Pemigatinib, the active ingredient in LuciPem, inhibits fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3. When FGFR2 is fused or rearranged, the receptor is persistently activated and signals for uncontrolled cell growth. LuciPem blocks this overactive pathway, slowing tumour progression through a targeted rather than broadly cytotoxic mechanism.

Indications

• Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, confirmed by a validated test.
• Adult patients after progression on at least one prior line of systemic therapy.

Dosage and Administration

The standard pemigatinib dose is 13.5 mg once daily for 14 consecutive days, then 7 days off, repeated in 21-day cycles. Tablets are swallowed whole with water, with or without food. The 4.5 mg strength supports dose reduction when needed. Phosphate levels, renal function and eye health should be monitored during treatment.

Side Effects

Common adverse reactions include hyperphosphatemia, diarrhoea, stomatitis, dry mouth, fatigue, nausea and alopecia. Serous retinal detachment is a serious risk requiring prompt reporting of any visual changes and ophthalmologic monitoring. Dry eye, nail disorders and liver enzyme elevations are also seen, with most events being mild to moderate.

Storage

Store LuciPem below 25°C in the original package, away from moisture and direct light, out of the reach of children. Use before the printed expiry date.

Why Choose the GLT?

GLT sources LuciPem through a documented Lao supply chain and confirms each batch against the manufacturer's details before shipping. Lao generics of pemigatinib typically cost a fraction of the originator's US list price, making FGFR-targeted therapy sustainable for long-term treatment. We provide clear purchase documentation and direct contact for ongoing support.

How to Order LuciPem from GLT

To order LuciPem 4.5 mg (14 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and whether you require a prescription or purchase order. We confirm batch details and lead time before dispatch.

FAQ

Is LuciPem the same as Pemazyre? LuciPem contains the same active ingredient (pemigatinib) at the same dose as Pemazyre; it is a generic manufactured in Laos by Lucius Pharmaceuticals.

What is LuciPem used for? It treats cholangiocarcinoma with an FGFR2 fusion or rearrangement in previously treated adults.

How do I order LuciPem? Contact GLT on WhatsApp or email; we supply LuciPem to international buyers.